← Eichor
Condition: Smoldering Multiple Myeloma Smm Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Smoldering Multiple Myeloma Smm

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
Phase 2 · 1 location(s) · University of Rochester · NCT05597345Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-
Phase 2 · 1 location(s) · Carl Ola Landgren, MD, PhD · NCT06100237Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution
Phase N/A · 4 location(s) · Azienda USL Reggio Emilia - IRCCS · NCT07214324Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
Phase 2 · 2 location(s) · University College, London · NCT06762769A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment o
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT05055063A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined S
NA · 8 location(s) · Memorial Sloan Kettering Cancer Center · NCT05640843Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Phase N/A · 7 location(s) · Dana-Farber Cancer Institute · NCT02269592A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Phase 3 · 2 location(s) · Regeneron Pharmaceuticals · NCT07393282A Prospective Multicenter Study of the Effects of Plant-based Diets on Gut Microbiome and Derived Metabolites in Patient
NA · 5 location(s) · Ciceri Fabio · NCT07069751Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
Phase 2 · 25 location(s) · Stichting European Myeloma Network · NCT06183489Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions
Phase N/A · 1 location(s) · University of Miami · NCT05361694Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple
NA · 1 location(s) · Roswell Park Cancer Institute · NCT05312255Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Phase 3 · 747 location(s) · ECOG-ACRIN Cancer Research Group · NCT03937635BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06745687CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
Phase N/A · 1 location(s) · Wake Forest University Health Sciences · NCT06644625The Indiana Myeloma Registry
Phase N/A · 1 location(s) · Indiana University · NCT03616483Whole Body MRI in Oncology
Phase N/A · 3 location(s) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRS · NCT06895291Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
Phase N/A · 1 location(s) · M.D. Anderson Cancer Center · NCT02726750Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma
Phase 2 · 1 location(s) · PETHEMA Foundation · NCT06574126A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
Phase N/A · 1 location(s) · Peking University First Hospital · NCT05283993The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma
Phase 1/Phase 2 · 1 location(s) · Oslo University Hospital · NCT05841550Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
Phase N/A · 1 location(s) · M.D. Anderson Cancer Center · NCT05136807European Myeloma Network (EMN) Sample Project
Phase N/A · 41 location(s) · European Myeloma Network B.V. · NCT06237803A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gam
NA · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06055894Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Phase 2 · 3 location(s) · Irene Ghobrial, MD · NCT05469893Registry for Adults With Plasma Cell Disorders (PCD's)
Phase N/A · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT03717844Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial
Phase N/A · 1 location(s) · University of Utah · NCT06212323Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
Phase N/A · 4 location(s) · Fondazione IRCCS Policlinico San Matteo di Pavia · NCT06383143A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple My
Phase 2 · 39 location(s) · Regeneron Pharmaceuticals · NCT06140524Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multipl
Phase 2 · 1 location(s) · Emory University · NCT04776395
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.